The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase III clinical trials with anamorelin HCl, a novel oral treatment for NSCLC cachexia.
Amy Pickar Abernethy
Employment or Leadership Position - Advoset; American Associate of Hospice and Palliative Medicine; Orange Leaf Associates
Consultant or Advisory Role - Novartis; Pfizer
Research Funding - BioVex; DARA BioSciences; Helsinn Therapeutics; Mi-Co; Pfizer
Jennifer S. Temel
No relevant relationships to disclose
David Currow
No relevant relationships to disclose
Lyon L. Gleich
Consultant or Advisory Role - Medpace
John Friend
Employment or Leadership Position - Helsinn Therapeutics